This Form 8-K filing by AbbVie Inc., dated February 5, 2025, announces the company's entry into a new revolving credit agreement on January 30, 2025. This agreement establishes an unsecured revolving credit facility of up to $3.0 billion, maturing on January 30, 2030. It allows AbbVie to borrow funds on an unsecured basis at variable interest rates while maintaining certain covenants.

AbbVie had no borrowings outstanding under this agreement as of the effective date. Additionally, its existing $5.0 billion revolving credit facility maturing in March 2028 remains in effect, bringing the company’s total available revolving credit facilities to $8.0 billion.